Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL

Active:	Yes
Cancer Type:	Cancer-Related Syndrome	NCT ID:	NCT03666000
Trial Phases:	Phase I	Protocol IDs:	PBCAR0191-01 (primary) NCI-2019-01892
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Imugene Limited
NCI Full Details:	http://clinicaltrials.gov/show/NCT03666000

Summary

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation,
and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an
allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.

Objectives

This is a multicenter, nonrandomized, open-label, parallel assignment, dose-escalation,
and dose-expansion study to evaluate the safety and tolerability, find an appropriate
dose to optimize safety and efficacy, and evaluate clinical activity of azer-cel in
participants with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL)
and non-Hodgkin lymphoma (NHL). Before initiating azer-cel, participants will be
administered lymphodepletion (LD). At Day 0 of the Treatment Period, participants will
receive an intravenous (IV) infusion of azer-cel. All participants will be monitored
through D720 or progression. All participants who receive a dose of azer-cel will be
followed in a separate long-term follow-up (LTFU) study for up to 15 years after exiting
this study.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.